Zeiger A R, Tuazon C U, Sheagren J N
Infect Immun. 1981 Sep;33(3):795-800. doi: 10.1128/iai.33.3.795-800.1981.
Sera from patients with endocarditis and bacteremia due to Staphylococcus aureus were compared for peptidoglycan-binding capacity with those from normal blood donors. Those patients treated with beta-lactam antibiotics had higher antigen-binding levels than normal donors and patients treated exclusively with vancomycin (P less than 0.01). The factor responsible for this activity was purified by affinity chromatography from a normal donor and shown to be an immunoglobulin. Specificity studies indicated that the immunodominant determinant was a peptide sequence found in peptidoglycan precursors. Since soluble peptidoglycan molecules having the precursor peptide sequence are known to be secreted by some gram-positive bacteria like Micrococcus luteus when grown in the presence of beta-lactam antibiotics, these soluble molecules may constitute the "natural" immunogen. Such a hypothesis is consistent with the study of the peptidoglycan-binding capacities in the sera of these patients during the course of treatment. For most of the responding patients studied (four of four with bacteremia and seven of nine with endocarditis), a significant increase in peptidoglycan-binding capacity was observed in sera taken 1 to 5 weeks after the initiation of beta-lactam antibiotic therapy (compared with the initial serum studied). No such increase in the peptidoglycan-binding capacity over a similar time span was noted in the sera of people not receiving beta-lactam antibiotics (none of seven).
将患有金黄色葡萄球菌引起的心内膜炎和菌血症患者的血清与正常献血者的血清进行肽聚糖结合能力比较。接受β-内酰胺类抗生素治疗的患者的抗原结合水平高于正常献血者和仅接受万古霉素治疗的患者(P小于0.01)。通过亲和层析从一名正常献血者中纯化出负责这种活性的因子,结果表明它是一种免疫球蛋白。特异性研究表明,免疫显性决定簇是在肽聚糖前体中发现的一个肽序列。由于已知当在β-内酰胺类抗生素存在下生长时,一些革兰氏阳性菌如藤黄微球菌会分泌具有前体肽序列的可溶性肽聚糖分子,这些可溶性分子可能构成“天然”免疫原。这样的假设与这些患者在治疗过程中血清中肽聚糖结合能力的研究结果一致。对于大多数所研究的有反应的患者(菌血症患者4例中的4例以及心内膜炎患者9例中的7例),在开始β-内酰胺类抗生素治疗后1至5周采集的血清中观察到肽聚糖结合能力显著增加(与最初研究的血清相比)。在未接受β-内酰胺类抗生素的人的血清中(7例均无),在类似的时间段内未观察到肽聚糖结合能力有这样的增加。